الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 119 |  |  |
| | | from | 119 | | |
Abstract
Diabetic kidney disease is one of the numerous consequences of diabetes mellitus, a metabolic illness defined by hyperglycemia owing to impaired insulin production, faulty insulin action, or both. Diabetes mellitus is a serious public health problem impacting millions of people throughout the globe.
Fetuin-A is a polymer that has several physiological functions, including as a modulator of insulin and an inhibitor of ectopic calcification. It is also involved in the development of diabetes, renal disease, and cancer. High levels of circulating fetuin-A have been linked to an increased risk of type 2 diabetes in several studies. Fetuin-A is also a nutritional inflammation marker. Several investigations have shown that fetuin-A levels are low in the blood of patients on continuous dialysis and are much lower in those with end-stage renal disease.
The Medical Department at Minia University Hospital conducted this prospective hospital-based research between June 2021 and February 2022. A minimum of 45 participants were divided into the following categories for the study:
group (I) functioned as a control, and its members were all healthy volunteers who were neither receiving hemodialysis or suffering from diabetes.
Patients with diabetes who also required hemodialysis made up group (II) (DM + HD group; n=15).
Non-diabetic hemodialysis patients (n=15) formed group III HD (HD group).
This research aims to better understand the impact and significance of Fetuin-A in hemodialysis patients with and without diabetes.
All of the contestants were put through the following.
One, a comprehensive review of the past is performed.
In-depth health checks and general health evaluations.
3.Experiments in a Lab (CBC, RBS, HbA1C, urine analysis, kidney function, liver function, etc..).
Fetuin-A concentration in blood plasma or serum 4.
The following is a synopsis of the data collected:
Dialysis groups (group Ii & Iii) had substantially greater mean age compared to the control group, although there were no considerable variations for sex (p=0.70), body mass index (p=0.98), or duration of dialysis (p=0.92). There were also a disproportionately high frequency of hypertensive и cardiac illnesses in group III.
There was a statistically significant variation in SBP across groups (the greatest SBP was seen in group III (132.3 20.1) and the lowest was seen in the treatment group (113.3 11.6), p 0.01). In comparison to the control group, those in the dialysis groups had considerably lower core body temperatures. DBP (p=0.18) and HR (p=0.61) showed no significant group differences.
There were three times as many incidences of pallor in the dialysis patient groups as there were in the control group (20% in group I vs. 73.3% in group II and III, p0.01). In addition, there were more incidences of stomach malaise in the DM+HD group (p=0.023) than in either of the other two different groups (p0.01).
group III (DM+HD) had substantially higher mean blood sugar levels at random and HbA1C than groups I and II (p0.03).
Dialysis patients (groups II and III) were found to have considerably greater levels of urea and createnine than the control group, despite the fact that the two groups were otherwise similar.
The results revealed that there were substantial differences in total cholesterol between the two intravenous fluids groups and the control group, with the highest level found in team (III) (203.3 30.6), followed by gang (II) (196.1 29.7) with no significant difference, and the lowest level found there in control group (168.7 21.7). group (II) would have the highest triglyceride level, which was statistically different from the other two groups (p0.01).
The primary results of the present study revealed that there were substantial disparities in pre-dialysis Fetuin-A levels among the three groups studied (its highest was in the DM+HD group, 92.5 10.6 mg/l, followed by the HD group, 77.9 15.4 mg/l, however the minimum level was noticed with in control group, 58.7 13.6 mg/l, p 0.01). Similar patterns of findings were seen after dialysis, with the DM+HD group exhibiting substantially higher Fetuin-A levels than the HD alone group (67.8 11.2 vs. 53.7 13.6 mg/l). In addition, the findings demonstrated that Fetuin-A levels were considerably lower in all groups post-dialysis versus pre-dialysis values (p 0.01).
The levels of Fetuin-A were found to be considerably greater in the sick groups (groups II and III) than in the healthy controls (p 0.01). When contrasted with the control group, the Fetuin-A levels of both group (II) and group (III) were statistically (p 0.01) greater.
Age, SBP, Rps, HbA1C, urea, creatinine, and T. cholesterol were all shown to have a positive connection with Fetuin-A concentration (p0.01).
Hypertension sufferers had a greater Fetuin-A level than non-HTN cases (87.3 16.3 vs. 71.5 14.6, p0.01). Further, the Fetuin-A level in cardiac instances is greater than in non-cardiac cases (93.712.7 vs. 71.915.6) (p0.01).